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ABSTRACT Small-animal models have been used to obtain many insights regarding
the pathogenesis and immune responses induced following infection with human
respiratory syncytial virus (hRSV). Among those described to date, infections in cot-
ton rats, mice, guinea pigs, chinchillas, and Syrian hamsters with hRSV strains Long
and/or A2 have been well characterized, although clinical isolates have also been ex-
amined. Ferrets are also susceptible to hRSV infection, but the pathogenesis and im-
mune responses elicited following infection have not been well characterized. Here,
we describe the infection of adult ferrets with hRSV Long or A2 via the intranasal
route and characterized virus replication, as well as cytokine induction, in the upper
and lower airways. Virus replication and cytokine induction during the acute phase
of infection (days 0 to 15 postinfection) were similar between the two strains, and
both elicited high levels of F glycoprotein-speciﬁc binding and neutralizing antibod-
ies following virus clearance (days 16 to 22 postinfection). Importantly, we demon-
strate transmission from experimentally infected donor ferrets to cohoused naive re-
cipients and have characterized virus replication and cytokine induction in the upper
airways of infected contact animals. Together, these studies provide a direct compar-
ison of the pathogenesis of hRSV Long and A2 in ferrets and highlight the potential
of this animal model to study serological responses and examine interventions that
limit transmission of hRSV.
IMPORTANCE Ferrets have been widely used to study pathogenesis, immunity, and
transmission following human inﬂuenza virus infections; however, far less is known
regarding the utility of the ferret model to study hRSV infections. Following intrana-
sal infection of adult ferrets with the well-characterized Long or A2 strain of hRSV,
we report virus replication and cytokine induction in the upper and lower airways,
as well as the development of virus-speciﬁc humoral responses. Importantly, we
demonstrate transmission of hRSV from experimentally infected donor ferrets to co-
housed naive recipients. Together, these ﬁndings signiﬁcantly enhance our under-
standing of the utility of the ferret as a small-animal model to investigate aspects of
hRSV pathogenesis and immunity.
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Human respiratory syncytial virus (hRSV) belongs to the family Pneumoviridae and isan enveloped virus with a negative-sense single-stranded RNA genome (1). hRSV
is the most common cause of bronchiolitis and pneumonia in young children (2, 3) and
a signiﬁcant cause of morbidity and mortality in both elderly and immunocompromised
individuals (4). In older children and healthy adults, hRSV can cause mild cold-like
symptoms that resolve without major complications or speciﬁc treatment.
There are currently no licensed hRSV vaccines or speciﬁc antiviral therapies, although
monoclonal antibody (MAb) prophylaxis is effective in reducing hRSV-associated hospital-
izations in infants at risk of severe disease (5). While a number of hRSV vaccine candidates
have progressed to clinical trials (6), the recent failure of the only vaccine to complete phase
III highlights the challenge of providing protective efﬁcacy in humans (7). Animal models of
hRSV are critical for preclinical testing; however, these often fail to recapitulate particular
aspects of human disease. Animal models used to study hRSV include nonhuman primates
and chimpanzees as well as small-animal models, including cotton rats, ferrets, chinchillas,
hamsters, guinea pigs, andmice (reviewed in references 6 and 8). Most small-animal models
tend to be semipermissive for hRSV infection, requiring large inoculum doses for experi-
mental infection and accompanied by little or no clinical sign of disease. Despite these
limitations, mice and cotton rats in particular have been utilized to provide important
insights regarding pathogenesis and immunity to hRSV and were instrumental in the
development of some treatments (e.g., development of MAb prophylaxis for infants at high
risk of severe hRSV infection [9, 10]).
Ferrets have been widely used to study human inﬂuenza virus infection. Ferrets are
susceptible to human inﬂuenza viruses without requiring prior adaptation of the
viruses, develop clinical signs similar to those in human infections (such as fever,
sneezing, and lethargy), and possess a respiratory tract physiology similar to that of
humans, making them an ideal model for human inﬂuenza (11). Infected ferrets can also
transmit human inﬂuenza viruses to other naive ferrets through direct contact or by the
airborne route. Currently, far less is known regarding the utility of the ferret model to
study aspects of pathogenesis and immunity to hRSV infections. In this regard, intra-
nasal (i.n.) inoculation of neonatal or adult ferrets with hRSV was shown to achieve high
levels of virus replication in nasal tissues, although replication in the lungs was only
observed in infant ferrets (12–14). Recent studies utilizing intratracheal (i.t.) inoculation
with a low-passage-number clinical isolate of hRSV demonstrated virus replication in
the upper (nasal turbinates and trachea) and lower (bronchus and lungs) airways, with
hRSV antigens localized to epithelial cells in the trachea and bronchi (15). Higher titers
and prolonged shedding of hRSV was demonstrated following i.t. inoculation of ferrets
that were immunosuppressed with a combination of drugs used in transplantation (15).
The majority of studies in different animal models have used hRSV Long and/or A2,
as well as a range of clinical isolates. Since their derivation from the lower respiratory
tract of infants over 50 years ago (Long, 1956, Maryland, USA; A2, 1961, Melbourne,
Australia), hRSV strains Long and A2 have been propagated in cell culture and used
extensively in in vitro and in vivo studies. Therefore, the pathogenesis and immune
responses elicited by experimental infection with Long and A2 can be compared
between different animal models. Here, we infected adult ferrets by the i.n. route with
an equivalent infectious dose of hRSV strain Long or A2 and assessed virus shedding in
the upper respiratory tract (URT) using nasal wash (NW) samples and in the lower
respiratory tract (LRT). In addition, we report induction of a range of cytokines,
chemokines, and other inﬂammatory mediators in the URT and LRT of hRSV-infected
ferrets, as well as the induction of serum antibodies, including neutralizing antibodies.
Finally, we provide evidence of contact transmission from experimentally infected
donor ferrets to cohoused naive recipients for both strains of hRSV.
RESULTS
Characterizing experimental i.n. infection of ferrets with Long and A2 strains
of hRSV. Ferrets (n  4/group) were infected by the i.n. route with 105 PFU of hRSV
strain Long or A2 and clinical disease and virus shedding were assessed at various times
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postinfection (p.i.). On day 21 p.i., ferrets were rechallenged via the i.n. route with an
identical dose of homologous virus and monitored for an additional 7 days. A modest
increase in temperature was observed 2 days after primary infection but no other
trends were apparent (Fig. 1A). Ferrets maintained or increased weight over the 28-day
monitoring period (Fig. 1B) and clinical signs were minimal, consistent with previous
studies (14).
Following primary infection, low levels of viral RNA (vRNA) were detected in NW
samples at day 1 p.i., and shedding peaked at day 3 and day 7 for animals infected with
FIG 1 Viral replication in the upper respiratory tract following experimental i.n. infection with hRSV. Ferrets (n  4 per group)
were infected i.n. with hRSV Long (closed circles) or A2 (open circles) virus, and NW samples were collected every second day.
Temperature (A) and weight (B) were measured daily. (A and B) Means  standard deviations from 4 ferrets per group are
shown. (C) Viral shedding was quantiﬁed by real-time qPCR detection of the hRSV nucleoprotein (N) gene. (E) A ViroSpot (VS)
assay was developed to measure titers of infectious virus in NW. Representative VS images of NW samples from two ferrets
are shown at days 1, 5, and 9 p.i. (D) Titers of infectious virus in NW samples as determined by VS assay. Means  standard
deviations from 4 ferrets per group are shown in panels A and C. An arrowhead indicates reinfection with homologous virus
strain. Statistical signiﬁcance for virus shedding between viruses was analyzed by multiple t test with a Bonferroni-Dunn
correction (alpha of 0.05), without assuming a consistent standard deviation. No signiﬁcant differences were observed.
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Long or A2, respectively (Fig. 1C). vRNA was detected for up to 11 days in some animals.
We developed a ViroSpot (VS) assay to measure titers of infectious hRSV (see Materials
and Methods) and conﬁrmed that its sensitivity was similar to that of plaque assay (data
not shown). An example of a VS assay measuring titers of infectious virus in NW from
hRSV-infected ferrets is shown (Fig. 1E). Similar to vRNA, low levels of infectious virus
were detected at day 1 p.i., and shedding peaked on day 3 in animals infected with the
Long strain and at days 3 to 7 in animals infected with the A2 strain. Infectious virus was
cleared by day 9 (Fig. 1D). Statistical analyses showed no signiﬁcant differences
between shedding of vRNA or infectious virus between the two virus strains on any of
the days tested (data not shown). Note that the persistence of vRNA shedding in the
absence of infectious virus is also seen in the cotton rat model (16). Throat swabs were
measured alongside NW samples for a subset of ferrets, with equivalent results (data
not shown); thus, NW sampling was used for the remaining experiments.
Induction of inﬂammatory mediators in the upper respiratory tract following
experimental i.n. infection of ferrets with hRSV.We next used real-time quantitative
PCR (qPCR) to determine the expression of a range of inﬂammatory mediators in NW
samples collected at various times after direct i.n. infection of ferrets with the Long or
A2 strain of hRSV. Expression of interleukin-1 (IL-1) and IL-1mRNAs peaked on days
1 to 5, beta interferon (IFN-) peaked on days 3 to 5, and IFN-mRNA levels peaked on
day 7 (Fig. 2B to E). Increased expression of these proinﬂammatory cytokines coincided
with maximum levels of hRSV N mRNA (Fig. 2A) on days 5 to 7 for hRSV Long and days
5 to 9 for hRSV A2. Expression of IFN- and IFN- mRNAs correlated with expression of
hRSV N A2 mRNA (IFN-, r 0.6395, P 0.0057; IFN-, r 0.6447, P 0.0052; Pearson
correlation), while expression of IFN- mRNA strongly correlated with hRSV Long N
mRNA (r  0.6466, P  0.0001; Pearson correlation). Expression of granzymes A and B
peaked from days 9 to 11 as viral RNA was clearing (Fig. 2F to H). Compared to
uninfected controls, infection of ferrets with either Long or A2 induced a range of
additional chemokines and cytokines, including mRNAs for IL-6, IL-8, IL-10, IL-12p40,
IL-17, monocyte chemoattractant protein 1 (MCP-1), and tumor necrosis factor alpha
(TNF-), although no clear peaks in expression were observed (Fig. 2I to O). Compared
to levels in A2-infected ferrets, slightly higher levels of mRNA for some genes were
observed in animals infected with hRSV Long (e.g., IL-1, IFN-, IL-10, and IL-12p40), but
these differences generally were not signiﬁcant, although levels of IFN- and IFN-
mRNA were signiﬁcantly higher on day 9 in A2-infected ferrets.
hRSV can replicate throughout the respiratory tract following experimental i.n.
infection of ferrets. We assessed whether hRSV Long and A2 replicated throughout
the respiratory tract of ferrets following i.n. infection. As hRSV was detected at high
levels on days 3 to 7 in the NW of i.n.-infected animals (Fig. 1), we hypothesized that
day 5 p.i. represented an appropriate time to sample for virus replication throughout
the airways. We included a later time point (day 9) to assess if replication kinetics were
delayed in the lower airways and/or virus had been cleared at this time point. At day
5 p.i., hRSV was detected throughout the upper and lower respiratory tracts of infected
ferrets. Both Long and A2 strains were detected in the turbinates, oropharynx, and
trachea from the majority of animals (Fig. 3A). hRSV Long was detected in the lungs of
all infected animals, including in all 5 lobes of one ferret, in 3 lobes of two ferrets, and
in 1 lobe of the remaining ferret (Fig. 3A). Infection was more restricted in animals
infected with A2 virus, with virus detected in lung tissues of 3/4 infected ferrets. Virus
was detected in 3 lobes in two ferrets and in 1 lobe of the third ferret (Fig. 3A). Note
that viral titers were generally similar between the two strains and when comparing
individual tissues (Fig. 3B), and no statistical differences were observed.
At day 9 p.i., virus was detected in respiratory tissues from two animals infected with
Long and two animals infected with A2. Long virus was detected in URT tissues
(turbinates and oropharynx) from two animals and in the lung of one animal (middle
lobe), while A2 virus was detected only in the URT of two animals (Fig. 3A and B). In
future experiments, it would be useful to also determine titers of infectious virus to
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correlate levels of vRNA with titers of infectious virus in the lungs of RSV-infected
ferrets.
Induction of inﬂammatory mediators in the lungs of ferrets following experi-
mental i.n. infection with hRSV. We next assessed expression of inﬂammatory me-
FIG 2 Expression of inﬂammatory mediator genes in nasal wash samples from ferrets after i.n. infection with hRSV. Ferrets were
infected via the i.n. route with hRSV Long or A2 virus. NW samples collected at various times p.i. were assayed for mRNA for the
indicated genes using real-time qPCR assays. Reference samples from uninfected ferrets are indicated at day 0, with a fold change of
1. Data are from a single experiment (n  4 animals/group). Statistical signiﬁcance for cytokine expression between viruses was
analyzed by a multiple t test with a Bonferroni-Dunn correction (alpha of 0.05) without assuming a consistent standard deviation (*,
P  0.05; **, P  0.01, ***, P  0.001).
Ferret Model of Respiratory Syncytial Virus Infection Journal of Virology
February 2018 Volume 92 Issue 4 e01322-17 jvi.asm.org 5
 o
n
 August 1, 2018 by University of Queensland Library
http://jvi.asm.org/
D
ow
nloaded from
 
diators in the lower airways. For these analyses, we assessed cytokine levels in individ-
ual lung lobes obtained from (i) uninfected animals or (ii) animals at day 5 p.i. with
hRSV. Note that data from A2/Long were combined and that virus-positive and
virus-negative lobes (as seen in Fig. 3A) were assessed independently. First, we con-
ﬁrmed that mRNA for IFN-, IL-1, IL-1, granzyme A, granzyme B, IFN-, IL-10, and
IL-17 were signiﬁcantly higher in virus-positive lobes than in lobes from uninfected
animals (Fig. 4, *). In contrast, no signiﬁcant differences were noted in levels of IFN-,
IL-6, IL-12p40, MCP-1, TNF-, or IL-8 (data not shown). Of note, IFN-, granzyme A,
granzyme B, and IL-17 were also signiﬁcantly upregulated in virus-negative lobes from
infected animals compared to uninfected animals, whereas IL-1, IL-1, IFN-, and IL-10
FIG 3 hRSV strains Long and A2 can replicate throughout the respiratory tract of ferrets after i.n. inoculation. Ferrets were
infected via the i.n. route with hRSV Long or A2 virus and tissues collected on day 5 or 9 p.i. Levels of vRNA for the viral
N gene were determined in tissue homogenates by real-time quantitative RT-PCR assay. (A) Diagrammatic representation
of virus spread (indicated by an asterisk) throughout the respiratory tract: 1, turbinates; 2, oropharynx; 3, trachea; 4, left
cranial lobe; 5, left caudal lobe; 6, right caudal lobe; 7, middle lobe; 8, right cranial lobe. Figure adapted from reference 37.
(B) Virus load in different tissues from the respiratory tract of ferrets. Results for individual animals are shown (n 4/group),
and the horizontal line represents the median value. The dotted line indicates the limit of detection. Titers for each tissue
were compared between virus strains using the Mann-Whitney U test.
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FIG 4 Detection of inﬂammatory mediators in the lung after hRSV infection. Ferrets were infected via
the i.n. route with hRSV Long or A2 virus. Lung lobes were collected on day 5 after infection and
assayed for mRNA for the indicated genes by real-time qPCR. Note that data from A2/Long were
combined and samples were classiﬁed as virus positive or virus negative based on vRNA results
described in Fig. 3. Circles represent individual lung lobes from up to 4 ferrets, and the horizontal
line represents the mean value for each mediator. For each graph, qPCR data ﬁrst were expressed
relative to values for lobes from uninfected animals and then normalized to ATF4, HPRT, and GAPDH
housekeeping genes. Values for virus-positive and virus-negative lobes from hRSV-infected animals
then were expressed as fold change relative to the corresponding lobes from uninfected animals. For
statistical analyses, inﬂammatory mediators were compared between virus-positive lobes and lobes
from uninfected animals (*, P  0.05; **, P  0.01, ***, P  0.001; ****, P  0.0001), between
virus-negative lobes from infected animals and lobes from uninfected animals (, P  0.05; , P 
0.01; , P  0.001; , P  0.0001), and between virus-positive and virus-negative lobes
from infected animals (, P  0.05; , P  0.01; , P  0.001; , P  0.0001). Note that
the data did not show a normal distribution; therefore, ROUT could not be used to remove outliers.
Instead, Kruskal-Wallis one-way analysis of variance (ANOVA) with Dunn’s multiple-comparison test
was used.
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were not (Fig. 4, ). Levels of IL-1 and IL-1 were signiﬁcantly higher in virus-positive
lobes than virus-negative lobes from infected animals, suggesting that localized virus
replication is important for expression of these cytokines (Fig. 4, ). Note that inde-
pendent analysis of virus-positive lobes from A2- or Long-infected animals showed no
signiﬁcant differences between virus strains in levels of IFN-, IL-1, IL-1, granzyme A,
granzyme B, IFN-, IL-10, and IL-17 (data not shown).
Characterization of humoral responses elicited in ferrets following experimen-
tal i.n. infection and rechallenge with hRSV. We developed two assays to charac-
terize humoral responses elicited in ferrets following i.n. infection with hRSV Long or A2
(as seen in Fig. 1 and 2). First, an enzyme-linked immunosorbent assay (ELISA) was used
to determine titers of serum antibodies capable of binding the recombinant F glyco-
protein of hRSV. Antibodies were measured by ELISA at baseline (i.e., day 0 relative
to infection) and at day 16 or 21 p.i. in 2 independent experiments. Titers of F
glycoprotein-speciﬁc antibodies were low at day 0 but increased markedly by days 16
and 21 (Fig. 5A). When expressed as a fold change relative to the level on day 0 (Fig.
5B), titers had increased 1,000- to 10,000-fold by day 21 p.i. While there was a tendency
for the fold changes to be higher in sera obtained at day 21 than at day 16, this was
not signiﬁcant for either virus strain. Together, these data demonstrate that experi-
mental i.n. infection with either A2 or Long strain induces high levels of F glycoprotein-
speciﬁc antibodies by day 21 p.i.
FIG 5 Humoral responses elicited following hRSV infection of ferrets by i.n. inoculation. Sera were collected
from animals immediately prior to i.n. infection (day 0) or on day 16 (experiment 1) or 21 (experiment 2)
after infection and assayed by ELISA (to detect antibodies capable of binding hRSV F glycoprotein) (A and
B) or by ViroSpot microneutralization (VS MN) assay for neutralizing antibodies (C, D, and E). (C) A VS MN
assay was developed to measure titers of neutralizing antibodies in ferret serum. Representative images of
a VS MN assay using day 0 and day 21 serum samples from a single ferret are shown, including a cell control
(CC; 1/4 are shown) and virus control (VC; 1/4 are shown). For panels A, B, D, and E, results from individual
animals infected with hRSV Long (closed circles) or A2 (open circles) are shown. For panels A and D,
individual titers are shown and the horizontal line represents the GMT. For panels B and E, fold change
compared to day 0 are shown and the horizontal line indicates median value.
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We next developed a microneutralization (MN) assay based on the VS assay used to
measure infectious virus (Fig. 1B). First, we used the MN assay to assess the neutralizing
activity of control samples from BEI Resources against A2 and Long strains of RSV. We
obtained MN titers for positive-control (NR-21973 immune globulin; A2 titer, 2,560;
Long titer, 5,120) and negative-control (NR-49447 human serum IgG depleted; A2 titer,
20; Long titer, 20) samples. We next examined MN titers in ferrets at different times
after hRSV infection. A representative example of the MN assay with results using serum
from a single ferret on days 0 and 21 is shown (Fig. 5C). This MN assay was used to
determine titers of neutralizing antibodies against the homologous challenge strain of
hRSV.
While MN titers (geometric mean titers [GMT] with 95% conﬁdence intervals [95%
CI]) were generally low at day 0, they were signiﬁcantly higher for the Long strain than
for the A2 strain (GMT [95% CI] for Long, 25.9 [19.2, 35.0]; A2, 19.3 [18.9, 19.6]; P 
0.0033 by Mann-Whitney test) (Fig. 5D). Low-level neutralizing activity observed in
naive sera from some animals may reﬂect the presence of serum inhibitors (rather than
antibodies), as reported for inﬂuenza and other viruses (17). Despite this, neutralizing
antibodies were induced following experimental infection of ferrets, with titers to the
Long strain reaching similar high levels at 16 or 21 days p.i. (GMT [95% CI] for day 16,
452.5 [45.6, 4,496]; day 21, 640 [134.5, 3,045]) (Fig. 5D), while titers to the A2 strain were
lower on day 16 than day 21 p.i. (GMT [95% CI] for day 16, 223.4 [13.4, 3,724]; day 21,
1,522 [876.9, 2,642]) (Fig. 5D). This difference in kinetics was also reﬂected in the fold
change over time for each ferret, with a median fold change of 24 at days 16 and 21
for ferrets infected with the Long strain and a median fold change of 32 at day 16 and
128 at day 21 for ferrets infected with the A2 strain (Fig. 5E). Of note, one ferret infected
with A2 did not seroconvert (Fig. 5D and E).
Given there were no major differences between antibody responses elicited follow-
ing experimental i.n. infection with either hRSV Long or A2, data were pooled for
further analyses. First, we noted a high level of correlation between the titers for the
ELISA and VS MN assay (r  0.9464, P  0.001; data not shown). We next assessed the
relationship(s) between the antibody titer achieved after infection and the kinetics of
virus shedding for ferrets infected by the i.n. route with hRSV. No signiﬁcant correla-
tions were observed between (i) the peak virus load or (ii) the number of days of
shedding 104 copies/100 l NW and titers of F glycoprotein-speciﬁc or neutralizing
antibodies (data not shown). Note that the longer the time from the start of virus
shedding until the collection of serum, the higher the titer of F glycoprotein-speciﬁc
(ELISA) or neutralizing (VS MN) antibodies achieved (r  0.5639 and P  0.0229 for
ELISA and r  0.6049 and P  0.0131 for VS MN; data not shown).
We rechallenged some of the ferrets to determine if the level of antibodies achieved
after primary infection could be boosted. Two ferrets were rechallenged with Long virus
and two others were rechallenged with A2 virus 21 days after a primary infection. Levels
of vRNA were very low, none of the ferrets shed detectable infectious virus after
rechallenge, and no clinical signs were detected (Fig. 1A to D, arrowheads). There was
no change in antibody titers from the time of rechallenge to 7 days after rechallenge,
when animals were killed (GMT [95% CI] at day 21 for Long of 1,280 [0] and A2 of 2,560
[0]; GMT [95% CI] at day 28 for Long of 1,280 [0] and A2 of 2,560 [0]) (data not shown).
These data suggest that neutralizing antibody titers of 1,280 are sterilizing following
i.n. infection with hRSV in the ferret.
Transmission between cohoused ferrets following experimental i.n. infection
of donor ferrets with A2 or Long strain of hRSV. We next investigated the ability of
hRSV to be transmitted between cohoused ferrets. Naive ferrets (recipients) were
cohoused for up to 3 weeks, with ferrets inoculated 1 day previously via the i.n. route
with hRSV (donor) (Fig. 6A), and virus shedding was assessed in all animals. hRSV Long
was shed by all infected donor ferrets for at least 5 days yet transmitted to only one of
the four recipient ferrets. Shedding of the virus in the recipient ferret was detected 3
days after the animals were cohoused (Fig. 6B). hRSV A2 was shed for at least 9 days by
all of the donor ferrets and was transmitted to 3 of 4 recipient ferrets. Shedding of the
Ferret Model of Respiratory Syncytial Virus Infection Journal of Virology
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virus in the recipient ferrets was detected from 5 to 9 days after the animals were
cohoused (Fig. 6C). Overall, transmission occurred when donor animals shed higher
peak amounts of virus (median peak shedding of virus for donors that transmitted virus
was 106.1 copies/100 l NW compared to 104.4 copies/100 l NW for donors that did
not transmit virus; P  0.0286) (Fig. 6D) and shed virus for a longer period of time
(median shedding of 12.5 days compared to 8 days; P  0.0286) (Fig. 6E). No recipient
animals that were infected and shed hRSV displayed weight loss or clinical signs (data
not shown).
Inﬂammatory mediators were also detected in NW from recipient ferrets that were
cohoused with infected donor ferrets and shed detectable levels of hRSV vRNA (Fig. 7).
For these analyses, data were pooled from A2 (3/4) and Long (1/4) recipient ferrets.
Note that samples were normalized to the ﬁrst day that the recipient ferret shed
detectable levels of virus in NW (i.e., irrespective of one animal ﬁrst shedding detectable
vRNA on experimental day 3 or 5, these are both adjusted to day 1 p.i. for analysis).
Inﬂammatory mediators induced following transmission of hRSV to cohoused recipients
were generally lower than those detected in donor ferrets (Fig. 2). Trends in cytokine
induction were not as distinct as those for donor ferrets; however, induction of a
FIG 6 hRSV can transmit between cohoused ferrets. (A) Experimental plan. Donor ferrets were infected via the i.n. route with hRSV Long (B) or A2 (C) virus. One
day later, donor animals were placed in clean cages and a naive recipient ferret was added. NW were collected on alternate days (donor, open triangles;
recipients, black diamonds). (B and C) Virus shedding was measured in NW samples by real-time qPCR assay detecting vRNA. (D and E) The peak of virus
shedding (D) and the number of days that detectable virus was shed in NW (E) was compared for donor ferrets that did or did not transmit virus to naive
contacts. Horizontal bars represent median values, and signiﬁcance was determined by Mann-Whitney test (P values are shown). Data are pooled from two
independent experiments, with 4 donors and 4 recipients for each virus.
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number of inﬂammatory mediators (e.g., IL-1, IL-1, L6, IL-8, MCP-1, and TNF- [Fig.
7]) showed an overall pattern similar to levels of vRNA (Fig. 7A). In contrast to data from
ferrets experimentally infected via the i.n. route with hRSV (Fig. 2F and G), distinct peaks
in granzymes A and B were not observed at days 11 to 13 p.i. in recipient ferrets (Fig.
7F and G).
FIG 7 Expression of inﬂammatory mediator genes in nasal wash samples from ferrets after hRSV infection by contact transmission. Naive
recipients were cohoused with donor ferrets that had been infected via the i.n. route with hRSV A2 or Long virus. Only recipient animals
that shed detectable hRSV were examined, and data have been adjusted such that the ﬁrst day that vRNA was detected in NW has been
designated day 1 p.i. Real-time qPCR assays were used to assess levels of different inﬂammatory mediators using mRNA derived from NW
samples. Data are from two independent experiments (n  4 animals/group).
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Note that while intranasal infection of donor ferrets with either hRSV strain induced
high levels of F glycoprotein-speciﬁc (Fig. 5A and B) and neutralizing antibodies (Fig. 5D
and E), animals were not kept alive long enough to conﬁrm seroconversion in recipi-
ents.
DISCUSSION
A recent study using a low-passage-number hRSV A clinical isolate to inoculate
ferrets via i.n./i.t. routes (105 50% tissue culture infectious doses [TCID50]/animal)
resulted in virus replication in the upper airways as well as in the trachea and lungs.
Virus titers were elevated and shedding was prolonged in hRSV-infected ferrets that
were treated with a combination of immunosuppressive compounds used in transplant
recipients (15). Our study focusing on the well-characterized A2 and Long laboratory-
adapted strains provides a number of important advances in our understanding of the
ferret model of hRSV infection. First, we conﬁrm that after i.n. inoculation, both strains
replicate efﬁciently in the URT of ferrets, and sporadic evidence of virus replication can
also be detected in the lungs. Second, we demonstrate that i.n. infection of ferrets
induces a range of cytokines and chemokines in both the upper and lower airways.
Third, we describe the induction of similar levels of F glycoprotein-speciﬁc and neu-
tralizing antibodies following i.n. infection of ferrets with either hRSV strain. Finally, we
demonstrate for the ﬁrst time that donor ferrets experimentally infected with hRSV can
transmit virus to cohoused naive recipient animals. Of interest, the A2 strain transmitted
more efﬁciently between cohoused ferrets (3/4) than the Long strain (1/4). Together,
these ﬁndings signiﬁcantly enhance our understanding of the utility of the ferret as a
small-animal model to investigate aspects of hRSV pathogenesis and immunity.
Currently, there are not enough data to determine if speciﬁc hRSV strains induce
differential disease, immunity, or transmissibility in the ferret model. Of note, variable
disease and differential immune responses have been noted following i.n. infection of
mice with laboratory strains (e.g., A2 and Long), as well as with different clinical isolates
(18, 19). Our data examining A2/Long virus load in the URT show titers and kinetics
similar to those recently reported following i.n. inoculation of immunocompetent
ferrets with a low-passage-number clinical isolate (subgroup A). However, no direct
comparison can be made for LRT viral replication, as the previous study only examined
replication within the lung after i.t., not i.n., inoculation (15). Of note, previous studies
using i.n. inoculation to inoculate ferrets with the Long strain reported virus replication
in the URT of both adult and infant ferrets but only in the lungs of infant animals (14).
The LRT replication of i.n.-delivered hRSV that we observed in adult ferrets may be a
consequence of differences in inoculum volume between the studies, as we used 0.5 ml
compared to a maximum of 0.2 ml in the previous work (14). Consistent with this, larger
inoculum volumes were associated with more uniform replication of inﬂuenza viruses
in the LRT of ferrets (20). Overall, our data using the well-characterized laboratory
strains A2 and Long provide a baseline for comparing pathogenesis, immunity, and
transmission of different hRSV strains, including recent clinical isolates, in the ferret
model.
We report for the ﬁrst time the induction of inﬂammatory mediators in the upper
and lower airways of healthy adult ferrets following i.n. infection with hRSV. Note that
the overall patterns and magnitude of cytokine/chemokine expressed in the URT was
very similar for ferrets infected with either the A2 or Long strain of virus. Our previous
studies showed that particular immune mediators (e.g., IL-6, IFN-, IFN-, MCP-1, IFN-,
granzyme A, and granzyme B) showed clear peaks of induction in the URT of ferrets
following i.n. infection of ferrets with type A (A/H1pdm, A/H3) or B (B/Yam) human
inﬂuenza viruses, while others (e.g., IL-12p40, IL-10, IL-17, and IL-8) were induced but
showed no clear peak (11). Moreover, only inﬂuenza A/H1pdm replicated in the LRT of
infected ferrets, inducing IL-6, IFN-, IFN-, MCP-1, IFN-, granzyme A, and granzyme B.
The inability of inﬂuenza A/H3 and type B viruses to replicate in the lung correlated
with a lack of detectable cytokines and/or chemokines at this site (11). Compared to
inﬂuenza infections, the patterns of chemokine and cytokine induction in the URT
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following hRSV infection were not as clear, although the induction of IL-1, IL-1, IFN-,
and IFN- mRNAs generally correlated with the kinetics of viral replication in the URT.
As for inﬂuenza virus, some mediators (e.g., granzyme A and B and IFN-) were
expressed in the URT at times that correlated with clearance of hRSV from this site. As
the hRSV inoculum was prepared in Hep2 cells, it may contain inﬂammatory mediators
that also could contribute to the induction of chemokines and cytokines in experimen-
tally infected animals. Moreover, this could be an additional factor contributing to the
different patterns of inﬂammatory mediators induced in animals infected experimen-
tally or following cohousing with infected donor ferrets. In future studies, we will
examine the ability of UV-inactivated hRSV to induce inﬂammatory mediators following
experimental infection of ferrets.
In the LRT, hRSV replication tended to be more sporadic, with vRNA often detected
in some, but not all, lung lobes of infected ferrets at day 5 p.i. Consistent with this, a
range of cytokines and chemokines could be detected in the lung, generally in lung
lobes from infected ferrets where vRNA was also detected. Like ferrets, the utility of the
cotton rat model is restricted by the limited pool of immunological reagents available
compared with those available for mice. However, qPCR demonstrated that following
i.n. inoculation of cotton rats, the Long strain rapidly induced inﬂammatory mediators
in the LRT (e.g., IFN-, IFN-, IL-1, IL-6, IP-10, MIP-1, RANTES, TNF-, and GRO [the
equivalent of human IL-8]), and their peak and decline tended to correlate with virus
peak (days 3 to 5 p.i.) and clearance (day 10 p.i.), respectively (13, 14).
Cotton rats have become a standard model for the evaluation of potential vaccines
and antivirals for hRSV, as well as for preclinical testing for anti-hRSV therapeutics.
Experimental infection of cotton rats with hRSV results in virus replication in the upper
and lower respiratory tract and induction of high titers of serum-neutralizing antibod-
ies, although infected animals do not tend to develop clinical signs of disease (8, 21).
Of interest, i.n. inoculation of ferrets with either Long or A2 induced high titers of
antibodies (F glycoprotein speciﬁc by ELISA or neutralizing by VS MN assay) by day 21
p.i. These ﬁndings were surprising, given that a previous study reported neutralizing
antibody titers to be weak or absent in 0-, 3-, 7-, 14-, or 28-day-old ferrets (with serum
taken at various time points, including 7, 14, 21, and 28 days p.i.) following i.n. infection
with the Long strain at an inoculum dose sufﬁcient to induce high titers (105 PFU/g)
of virus replication in the URT of all age groups and the LRT of infant ferrets (14). In fact,
in our study the titers of neutralizing antibodies induced in adult ferrets were similar to
those induced following i.n. infection of cotton rats with the Long strain (22). While the
potential of the ferret model to assess the effectiveness of potential vaccines and
antiviral agents has not been well explored, intranasal delivery of adenovirus-vectored
vaccines expressing hRSV F and/or G glycoproteins was reported to induce neutralizing
antibody responses and provided protection following challenge with hRSV A2 in a
dose-dependent manner (13).
In small-animal models of hRSV infection, inoculum doses used for experimental
infections generally (i) are in the range of 104 to 108 PFU/animal, (ii) are delivered by
the i.n. or i.t. route, and (iii) result in moderate to high levels of virus replication in the
upper airways and moderate to low levels in the LRT (reviewed in reference 5). Our
results using 105 PFU/ferret of hRSV Long or A2 for experimental i.n. infection are
consistent with earlier studies. Furthermore, we report that hRSV, in particular the A2
strain, transmitted to naive cohoused ferrets (transmission to 3/4 and 1/4 recipients for
A2 and Long, respectively). In previous studies, 1/7 mothers of i.n.-infected infant ferrets
developed antibodies to hRSV (14), suggesting that transmission occurs by close
contact. Our data extend these observations and provide clear evidence of transmission
between cohoused adult ferrets, allowing us to assess viral kinetics in contact animals
following infection acquired from a donor ferret with an inoculum dose and route of
infection that are likely to be more representative of natural hRSV infections in humans
(23). Note that viral titers in the URT of some recipient animals reached peak levels
similar to those in experimentally infected donor animals, implying that a high dose of
virus inoculum is not necessarily required to achieve efﬁcient replication in the upper
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airways of ferrets. In future studies, it will be of interest to determine if transmission of
hRSV to naive cohoused recipients results in any virus replication in the LRT, as seen
following experimental i.n. infection with Long or A2. While animal-to-animal transmis-
sion of hRSV (originally termed chimpanzee coryza agent) has been reported in
chimpanzees (24), our ﬁndings highlight the potential of ferrets as a small-animal
model to explore the ability of vaccines and antivirals to block hRSV transmission.
Further reﬁnement and investigation of hRSV transmission in ferrets is required,
including investigation of noncontact (or aerosol) transmission, as described for inﬂu-
enza (reviewed in references 11 and 25), as well as investigating contact and noncon-
tact transmission by hRSV isolates. While experimental i.n. infection was associated
with high levels of anti-RSV antibodies by day 21 p.i., it will be important to examine
a number of later time points to understand the timing of the peak and the decay of
anti-RSV antibodies in experimentally infected animals. Moreover, contact ferrets
showed little evidence of seroconversion by day 18 to 22 p.i. despite shedding peak
titers of vRNA similar to those of experimentally infected animals, possibly because the
interval between contact infection and serum sampling was too short. Further studies
are required to more thoroughly investigate the timing and kinetics of anti-RSV
antibody induction in recipient animals infected with hRSV. Overall, the ferret model of
hRSV infection and transmission has the potential to offer signiﬁcant advantages over
other small-animal models, in particular in assessing novel therapeutic (e.g., treatment
of infected donors) or prophylactic (e.g., treatment of naive recipients prior to intro-
duction of infected donor animals) interventions against hRSV, as well as the potential
for novel vaccines to limit transmission to vaccinated recipient animals.
MATERIALS AND METHODS
Ferrets. Ferrets (mean weight, 986 g; range, 780 to 1,220 g) were housed in the Bioresources Facility
at the Peter Doherty Institute for Infection. Experiments were conducted with approval from the
University of Melbourne Biochemistry & Molecular Biology, Dental Science, Medicine, Microbiology &
Immunology, and Surgery Animal Ethics Committee, in accordance with the NHMRC Australian code of
practice for the care and use of animals for scientiﬁc purposes.
Cells and viruses. Human epithelial type 2 (HEp-2) cells, a derivative of HeLa cells (26), were
passaged in Dulbecco’s modiﬁed Eagle’s medium (DMEM; Gibco) supplemented with 10% (vol/vol) fetal
calf serum (FCS) (Bovogen Biologicals Pty Ltd.), 2 mM L-glutamine (GlutaMAX; Gibco), nonessential amino
acids (Gibco), 0.55% (vol/vol) sodium bicarbonate (Gibco), 20 mM HEPES (Gibco), 200 U/ml penicillin
(Gibco), and 200 g/ml streptomycin (Gibco). The Long strain of hRSV (VR-26) was purchased from the
American Type Culture Collection (ATCC), and the A2 strain was obtained from the Department of
Microbiology and Immunology (DMI) at the University of Melbourne.
Growth of hRSV in HEp-2 cells. HEp-2 cells grown to 90% conﬂuence in tissue culture ﬂasks
(Corning) were inoculated with dilutions of hRSV (A2 or Long) and harvested when approximately 50%
of cells showed syncytium formation (generally 3 to 5 days p.i.). Flasks then were frozen at 80°C and
thawed rapidly at 37°C, and the cells and supernatant were collected and vortexed for 2 to 3 min. Cell
debris was pelleted by centrifugation, and clariﬁed supernatants were aliquoted, snap-frozen in liquid
nitrogen, and then stored at 80°C. Virus copy number was determined by real-time reverse
transcription-PCR (RT-PCR), and titers of infectious virus were quantiﬁed by plaque assay and/or ViroSpot
assay as described below. Analysis of our A2 and Long virus stocks conﬁrmed that there was no
signiﬁcant difference in the ratio of genome copy to infectious virus (mean ratios  standard deviations
[SD] were 36.5  21.2 and 64.9  56.0 for A2 and Long, respectively [P  0.379 by Student’s t test]).
Plaque assay and ViroSpot assay to determine titers of infectious hRSV. Titers of infectious hRSV
were determined by standard plaque assay on HEp-2 cells as described previously (27). Brieﬂy, HEp-2 cells
seeded into 6-well tissue culture plates were grown to 90 to 95% conﬂuence, washed with serum-free
maintenance medium (MM; serum-free DMEM supplemented with 2 mM GlutaMAX, nonessential amino
acids [Gibco], 0.55% [vol/vol] sodium bicarbonate [Gibco], 20 mM HEPES [Gibco], 200 U/ml penicillin
[Gibco], and 200 g/ml streptomycin [Gibco]), and inoculated with 1 ml of virus dilutions prepared in
MM. After incubation for 2 h at 37°C, virus inoculum was removed and 3 ml of overlay (MM supple-
mented with 2% FCS and 0.3% [wt/vol] agarose [Invitrogen]) and plates were incubated a further 7 days
at 37°C. After incubation, cell monolayers were ﬁxed in 1% (vol/vol) formalin (Sigma-Aldrich) and stained
with 0.05% (wt/vol) neutral red (Sigma-Aldrich), and plaque numbers were counted to determine virus
titer, expressed as PFU per milliliter.
A ViroSpot assay, modiﬁed from a similar assay developed to detect inﬂuenza virus (28, 29), was also
developed to determine titers of infectious hRSV. Serial dilutions of samples containing hRSV were
prepared in MM, and 100 l was added to conﬂuent Hep-2 cell monolayers in a 96-well plate. After
incubation for 2 h at 37°C, samples were removed and replaced with 100 l MM plus 100 l infection
medium (equal volumes of 6.4% [wt/vol] carboxymethyl cellulose [Sigma] and 2	 minimal essential
medium [Sigma]), and plates were incubated for 48 h at 37°C. Spots were detected using a chimeric
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monoclonal antibody produced in house based on the heavy and light chain variable regions of
motavizumab (30) and the human backbone sequences using previously described methods (31).
Chimeric human motavizumab was used at a concentration of 0.2 ng/well, followed by goat anti-human
IgG (H
L) horseradish peroxidase (HRP) conjugate (Merck Millipore) diluted 1:500. After washing, 50 l
TrueBlue peroxidase substrate (SeraCare) was added to allow for color development, and the reaction
was stopped with 200 l H2O. Plates then were washed and dried, and spots were counted using a
CTL-Immunospot S6 Macro analyzer with CTL Switchboard 2.6.0 (x86). Counts were used to determine
infectious titers of hRSV, and results are expressed as infectious counts (IC) per milliliter or similar. When
performed on 3 independent occasions, titers of infectious virus determined by plaque assay or by VS
assay differed by less than 2-fold (data not shown).
Virus infection of ferrets and virus transmission. Ferrets were anesthetized (12.5 mg/kg of body
weight ketamine and 2.5 mg/kg Ilium Xylazil-20 in a 1:1 [vol/vol] mixture; Troy Laboratories) and
inoculated by dropwise delivery of 105 PFU of hRSV in 0.5 ml into the nostrils. Ferrets were bled prior to
primary virus infection (day 0) and at the termination of the experiment. Animals were weighed and
visually inspected, and their temperature was measured daily using implanted temperature transponders
ﬁtted to identiﬁcation chips (LifeChip Bio-Thermo; Digivet). For i.n. infection experiments, ferrets were
housed in pairs in a HEPA-ﬁltered isolation unit. For contact transmission experiments, the i.n.-infected
(donor) ferrets were transferred into a new clean cage the day after infection and a naive (recipient) ferret
added to the cage. The proportion of weight change was calculated as the percent difference from the
weight at day of challenge for i.n.-infected ferrets or from the weight at day of addition to the cage for
recipient ferrets.
Collection of samples from the respiratory tract of ferrets. Nasal wash (NW), throat swab (TS), and
respiratory tissue samples were collected from naive and hRSV-infected adult ferrets. NW and TS were
collected under light sedation (5 mg/kg Ilium Xylazil-20; Troy Laboratories). NW were performed by
delivery of 1 ml phosphate-buffered saline (PBS) supplemented with 50 U/ml penicillin, 50 g/ml
streptomycin (SAFC Biosciences), and 1% (wt/vol) bovine serum albumin (BSA; Sigma-Aldrich) (NW
solution) into the nostril. Expelled liquid was collected and 4 separate aliquots prepared: 140 l was
immediately snap-frozen in liquid nitrogen and stored at 80°C for ViroSpot assay (see below), 140 l
was aliquoted into lysis buffer for vRNA extraction and quantiﬁcation (see below), 200 l was aliquoted
into 1 ml RNAprotect saliva reagent (Qiagen, Germany) for cytokine and chemokine mRNA quantiﬁcation
(see below), and the remainder was snap-frozen and stored at 80°C. vRNA extraction was performed
on the day of collection. For TS, the back of the throat and the upper palate were sampled using a sterile
transport swab (Interpath Services, Copan). The tip only was placed in 1 ml NW solution and vortexed
vigorously for 15 s, and the liquid was aliquoted as per NW samples. For collection of tissues, ferrets were
anesthetized and then euthanized by cardiac injection of pentobarbitone. Respiratory tissues (individual
lung lobes, nasal turbinates, oropharynx, and trachea) were incubated in RNAlater tissue collection RNA
stabilization solution (Ambion, Life Technologies, Australia) overnight at 4°C. Following incubation,
tissues were removed from solution and stored at 80°C until total RNA extraction could be performed.
Total RNA extraction. Cells in ferret nasal wash samples treated with RNAprotect saliva reagent
were pelleted and resuspended in 350 l RLT buffer. Total RNA was extracted using the RNeasy Micro
kit (Qiagen) according to the manufacturer’s instructions and eluted with 14 l RNase-free water. Total
RNA was extracted from ferret respiratory tissue samples using the RNeasy Maxi kit (Qiagen) according
to the manufacturer’s instructions. Brieﬂy, 3 ml RLT buffer containing 143 mM -mercaptoethanol was
added directly to the lung lobes, oropharynx, or trachea tissues in a gentleMACS M tube (Miltenyi Biotec).
The sample was homogenized using the gentleMACS dissociator instrument (Miltenyi Biotec). For nasal
turbinates, 5 ml RLT buffer containing 143 mM -mercaptoethanol was added directly to the frozen
tissue in a 50-ml tube and homogenized using a Polytron PT 2500E (ThermoFisher Scientiﬁc). The lysate
was clariﬁed twice by centrifugation at 3,000 	 g for 10 min. RNA was extracted using the animal tissue
protocol and eluted in 800 l. RNA purity was assessed for all samples by spectrophotometry (A260/A280).
Real-time PCR assays to detect ferret cytokine and chemokine mRNA. mRNA was isolated from
ferret NW samples as previously described (32) and from lung tissues as describe above. mRNA for
various ferret cytokines, chemokines, and housekeeping genes was quantiﬁed as previously described
(32, 33).
Generation of DNA plasmids and RNA standards. vRNA was isolated from cell-cultured A2 virus
using the QIAamp viral RNA minikit (Qiagen) according to the manufacturer’s instructions. The viral
nucleoprotein (N) gene was ampliﬁed from 5 l vRNA using the MyTaq one-step RT-PCR kit (BIOLi.n.E)
with gene-speciﬁc primers F (5=CTCTTAGCAAAGTCAAGTTGAATGATACAC3=) and R (5=TCAAAGCTCTACA
TCATTATCTTTTGGAT3=) according to the manufacturer’s instructions. The size of the product was
conﬁrmed by electrophoresis, puriﬁed using the QIAquick DNA gel extraction kit (Qiagen), and then
cloned into the pCR4-Blunt-TOPO vector according to the manufacturer’s instructions (Zero Blunt TOPO
PCR cloning kit for sequencing, with One Shot TOP10 chemically competent Escherichia coli; Invitrogen).
RNA standards were prepared from the pCR4-blunt-TOPO hRSV N plasmid using the Riboprobe in vitro
transcription system (Promega). Transcribed RNA was puriﬁed using the RNeasy minikit (Qiagen) and
treated with a Turbo DNA-free kit (Life Technologies) per the manufacturer’s instructions. Tenfold RNA
standards were prepared.
Real time RT-PCR quantiﬁcation of viral load in ferret nasal wash and throat swab samples.
vRNA was extracted from NW and TS using the QIAamp viral RNA minikit (Qiagen) according to the
manufacturer’s instructions. Total RNA was extracted from lung tissues as described above. Four
microliters of vRNA was used to amplify the hRSV N gene using the following combination of primers and
probe with the SensiFAST probe Lo-ROX one-step kit (BIOLi.n.E): F(1) primer, 5=GAGTTGAAGGRA TYTTT
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GCAGGA3=; F(2) primer, 5=GAGTTGAAGGRATYTTTGCAGGAT3=; R(1) primer, 5=AAAACTCCCCATCTTAGCA
TTACTTG3=; R(2) primer, 5=CCCCCACCGTAACATC ACTT3=; probe, 6-carboxyﬂuorescein-5=TTATGAATGCC
TATGGTKCAG3=-MGBNFQ. The RT-PCR consisted of 1 cycle of 45°C for 10 min and 95°C for 2 min and 45
cycles of 95°C for 5 s, 60°C for 30 s using the 7500 Fast real-time system (Applied Biosystems) and 7500
Fast system SDS software, version 1.4.0. The threshold was automatically set and threshold cycle (CT)
determined. Samples, no-template controls, RNA standards, and positive (pCR4-blunt-TOPO hRSV N) and
negative controls were included in all real-time RT-PCR assays. The detection limit was 10 copies.
ELISA to detect antibodies speciﬁc to the F glycoprotein of hRSV. An ELISA was developed to
measure titers of antibodies capable of binding to the F glycoprotein of hRSV. Prior to assay, ferret sera
were pretreated with receptor-destroying enzyme II (RDE; 1:5, vol/vol; Denka Seiken Co. Ltd.) for 18 to 20
h at 37°C, and the reaction was stopped by addition of an equal volume of 1.6% (wt/vol) sodium citrate
and incubation at 56°C for 30 min. Individual wells of 96-well ﬂat-bottom plates (Nunc MaxiSorp;
Invitrogen) next were coated with 50 l of a 1-g/ml preparation of recombinant hRSV F glycoprotein
diluted in PBS. Note that a soluble recombinant F glycoprotein incorporating amino acids 1 to 106 and
144 to 511 from RSV F of laboratory strain A2 and a carboxyl-terminal trimerization domain was produced
in Chinese hamster ovary cells and puriﬁed by immunoafﬁnity chromatography in a manner similar to
that previously described for the Ebola GP ectodomain (34). Prefusion conformation was conﬁrmed by
reactivity with monoclonal antibodies D25 and MPE8 (35, 36). After overnight incubation at 4°C, plates
were washed three times with 100 l/well of PBS containing 0.05% (vol/vol) Tween (PBSTw) and then
incubated with 200 l/well blocking solution (5%, wt/vol, skim milk powder in PBSTw) at room
temperature for30 min. Serial 1/2-log dilutions of ferret sera were prepared in blocking solution, added
to 96-well plates at 50 l/well, and incubated for 60 min at 37°C. After washing, all wells received 50
l/well of goat anti-ferret IgG (H
L) HRP conjugate (Abcam) diluted 1:10,000 and were incubated at 37°C
for 60 min. Plates then were washed before addition of TMB 2-component microwell peroxidase
substrate (SeraCare). The color reaction was stopped by addition of 50 l/well of 1 M sulfuric acid before
optical density was determined at a wavelength of 450 nm.
VS MN assay for hRSV. A ViroSpot microneutralization (VS MN) assay was performed to detect
neutralizing antibodies to hRSV. The assay was modiﬁed from a similar VS MN assay developed to detect
neutralizing antibodies against inﬂuenza virus (28, 29). The following human serum samples were
obtained from BEI Resources for testing in the MN assay: positive-control immune globulin (lot RSV-1;
NR-21973) and negative-control human serum, IgG depleted (lot 63499869; NR-49447). Ferret sera were
treated with RDE and then heat inactivated at 56°C for 30 min in human serum that was heat inactivated
at 56°C for 30 min. Serial 2-fold dilutions of sera were prepared in MM and incubated with an equivalent
volume of hRSV (diluted in MM to give 250 to 450 spots/well in virus-only control wells) for 60 min at
37°C before 100 l/well of virus-serum mix was added to 96-well plates containing conﬂuent HEp-2 cell
monolayers. After incubation for 2 h at 37°C, the virus-serum mix was removed and replaced with 100
l MM plus 100 l infection medium (equal volumes of 6.4% [wt/vol] carboxymethyl cellulose [Sigma]
and 2	 minimal essential medium [Sigma]), and plates were incubated for 48 h at 37°C. After washing,
50 l TrueBlue peroxidase substrate (SeraCare) was added to allow for color development, and the
reaction was stopped with 200 l H2O. The plates were washed once and resuspend in 200 l MilliQ H2O
for 30 min at room temperature, after which they were tapped dry on a paper towel and the plate left
to dry upside down. Spots were detected and counted as described above for the infectious VS assay.
VS MN titers were determined using the reciprocal of the highest serum dilution causing a 50% reduction
in spots compared to virus-only control wells.
Statistical analysis. Statistical analyses were conducted using Prism version 6.0g and are described
in the ﬁgure legends.
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